News

Ovarian Cancer Will Continue to be Sequenced After The Cancer Genome Atlas Ends

The Cancer Genome Atlas (TCGA), a massive U.S. effort to genetically profile 10,000 tumors, has officially come to an end. The National Cancer Institute (NCI) has announced that it will continue to intensively sequence tumors in three cancers, ovarian, colorectal and lung adenocarcinoma, with an expanded... 

Palliative Care Consultation Improves Symptoms in Gynecologic Cancer Patients

A new study published in Gynecologic Oncology found that palliative care consultation is associated with improvement in symptom burden, the majority of which occurs within one day of consultation. Palliative care (or treatment) relieves symptoms such as pain, and reduces the suffering caused by cancer.... 

FDA Approves Olaparib for Ovarian Cancer

(December 19, 2014) The U.S. Food and Drug Administration (FDA) has approved AstraZeneca’s Olaparib (Lynparza) for advanced, BRCA-mutated ovarian cancer, the first approval of a drug in the PARP (poly ADP-ribose polymerase) inhibitor class. The FDA also approved Myriad Genetics’ BRACAnalysis...